Literature DB >> 9508526

Gastric transit and pharmacodynamics of a two-millimeter enteric-coated pancreatin microsphere preparation in patients with chronic pancreatitis.

M J Bruno1, J J Borm, F J Hoek, B Delzenne, A F Hofmann, J J de Goeij, E A van Royen, D J van Leeuwen, G N Tytgat.   

Abstract

It has been suggested that enteric-coated pancreatin microsphere (ECPM) preparations with sphere sizes larger than 1.7 mm pass through the stomach at a slower rate than a meal and therefore may be less efficacious in restoring pancreatic enzyme activity than preparations with smaller sphere sizes. The aim of this study was to investigate the gastric transit profile of a 2-mm ECPM preparation in relation to that of a solid meal and to simultaneously measure enzyme activities in eight patients with pancreatic exocrine insufficiency due to chronic pancreatitis. Gastric transit was assessed by double-isotope scintigraphy. A pancake was labeled with 99mTc. A 2-mm ECPM preparation was labeled with 171Er. Intraluminal pancreatic enzyme activities were assessed during a 6-hr period with the cholesteryl-[14C]octanoate breath test (for carboxyl ester lipase activity) and the N-benzoyl-L-tyrosyl-p-aminobenzoic acid/p-aminosalicylic acid (NBT-PABA/PAS) test (for chymotrypsin activity). The ECPM preparation passed through the stomach more rapidly (median 24 min) than the pancake (median 52 min, P < 0.05). During ECPM therapy, mean cumulative 14CO2 outputs rose significantly from 30% to 70% (P < 0.05), but remained below outcomes in healthy volunteers. Mean cumulative plasma PABA concentrations rose significantly from 46% to 87% (P < 0.05) and were not significantly different from outcomes in healthy volunteers. In chronic pancreatitis, a 2-mm ECPM preparation does not pass through the stomach more slowly than a solid meal, but in fact faster. Digestion of ester lipids and proteins showed an improvement to subnormal and normal levels, respectively.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508526     DOI: 10.1023/a:1018813229334

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholesteryl octanoate breath test.

Authors:  S Mundlos; P Kühnelt; G Adler
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

2.  Influence of exocrine pancreatic insufficiency on the intraluminal pH of the proximal small intestine.

Authors:  S K Dutta; R M Russell; F L Iber
Journal:  Dig Dis Sci       Date:  1979-07       Impact factor: 3.199

3.  Gastric secretion in chronic pancreatitis.

Authors:  R E Kravetz; H M Spiro
Journal:  Ann Intern Med       Date:  1965-11       Impact factor: 25.391

4.  Comparative in vitro and in vivo studies of enteric-coated pancrelipase preparations for pancreatic insufficiency.

Authors:  M Thomson; A Clague; G J Cleghorn; R W Shepherd
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-11       Impact factor: 2.839

5.  The pH-sensitive enteric-coated pancreatic enzyme preparations: an evaluation of therapeutic efficacy in adult patients with pancreatic insufficiency.

Authors:  S K Dutta; D K Tilley
Journal:  J Clin Gastroenterol       Date:  1983-02       Impact factor: 3.062

6.  Oral administration of a chymotrypsin-labile peptide--a new test of exocrine pancreatic function in man (PFT).

Authors:  K Gyr; G A Stalder; I Schiffmann; C Fehr; D Vonderschmitt; H Fahrlaender
Journal:  Gut       Date:  1976-01       Impact factor: 23.059

7.  Cholesteryl octanoate breath test. Preliminary studies on a new noninvasive test of human pancreatic exocrine function.

Authors:  S G Cole; S Rossi; A Stern; A F Hofmann
Journal:  Gastroenterology       Date:  1987-12       Impact factor: 22.682

8.  Comparison of four pancreatic extracts in cystic fibrosis.

Authors:  D W Beverley; J Kelleher; A MacDonald; J M Littlewood; T Robinson; M P Walters
Journal:  Arch Dis Child       Date:  1987-06       Impact factor: 3.791

9.  Gastric emptying of solids in man.

Authors:  S Holt; J Reid; T V Taylor; P Tothill; R C Heading
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

10.  [Pancreatic enzyme replacement in mucoviscidosis (CF): clinical evaluation of a gastric acid-resistant pancreatin preparation in encapsulated microtablet form].

Authors:  M Stern; C Plettner; R Grüttner
Journal:  Klin Padiatr       Date:  1988 Jan-Feb       Impact factor: 1.349

View more
  5 in total

Review 1.  Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century.

Authors:  Tony Trang; Johanna Chan; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

2.  Development of enteric submicron particle formulation of papain for oral delivery.

Authors:  Manu Sharma; Vinay Sharma; Amulya K Panda; Dipak K Majumdar
Journal:  Int J Nanomedicine       Date:  2011-09-23

3.  Turkish Gastroenterology Association, Pancreas Study Group, Chronic Pancreatitis Committee Consensus Report.

Authors:  Müjde Soytürk; Göksel Bengi; Dilek Oğuz; İsmail Hakkı Kalkan; Mehmet Yalnız; Mustafa Tahtacı; Kadir Demir; Elmas Kasap; Nevin Oruç; Nalan Gülşen Ünal; Orhan Sezgin; Osman Özdoğan; Engin Altıntaş; Serkan Yaraş; Erkan Parlak; Aydın Şeref Köksal; Murat Saruç; Hakan Ünal; Belkıs Ünsal; Süleyman Günay; Deniz Duman; Alper Yurçi; Sabite Kacar; Levent Filik
Journal:  Turk J Gastroenterol       Date:  2020-11       Impact factor: 1.555

4.  Comment on: "Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS".

Authors:  Karl-Uwe Petersen
Journal:  Drugs R D       Date:  2021-10-20

5.  Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis.

Authors:  Devi Mukkai Krishnamurty; Atoosa Rabiee; Sanjay B Jagannath; Dana K Andersen
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.